Definium Therapeutics, Inc.
DFTX
Rank in Stocks
#3533
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Share Price
$35.89
Market Cap
$4.82B
Change (1 day)
2.28%
Change (1 year)
183.94%
Country
US
Trade Definium Therapeutics, Inc. (DFTX)
Category
Healthcare
Stock price history for Definium Therapeutics, Inc. (DFTX)
Highest end of day price: $35.17 on 2026-10-01
Lowest end of day price: $4.81 on 2016-11-01
Lowest end of day price: $4.81 on 2016-11-01
Stock price history of Definium Therapeutics, Inc. from 2016 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 98.62% |
| 2025 | 74.98% |
| 2024 | 107.98% |
| 2023 | 34.70% |
| 2022 | -89.90% |
| 2021 | -40.72% |
| 2020 | 7,946.66% |
| 2019 | -31.09% |
| 2018 | -81.58% |
| 2017 | -37.50% |
| 2016 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $520.49 | 22.10% |
US
|
|
| $249.07 | 806.04% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $886.21 | 6.16% |
NL
|
|
| $752.87 | 7.40% |
CH
|
